{
    "nct_id": "NCT03582124",
    "official_title": "A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures",
    "inclusion_criteria": "* Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven\n* Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer\n* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2\n* Hemoglobin ≥ 9 gm/dL\n* White blood cell count > 3000/mm^3\n* Platelet count ≥ 100,000/mm^3\n* Serum creatinine ≤ 1.5 times upper reference range\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800\n* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment\n* History of infusion reactions to monoclonal antibody therapies\n* Pregnant or breastfeeding\n* Magnesium or potassium lower than the normal institutional values\n* Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis\n* Prisoners, institutionalized individuals, and patients unable to consent for themselves",
    "miscellaneous_criteria": ""
}